AI In Multiple Myeloma Patients

Overview

About this study

The objectives of this study are to determine the impact of type, dose, and duration of exogenous glucocorticoid therapy on development of adrenal insufficiency, iatrogenic Cushing syndrome and glucocorticoid withdrawal syndrome after cessation, to identify the predictors of severity of glucocorticoid withdrawal syndrome in patients tapering or discontinuing glucocorticoids, and to investigate the effect of glucocorticoid therapy on bone turnover parameters in patients with symptomatic multiple myeloma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18 and above.

  • Diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) criteria.

  • Plan to initiate exogenous glucocorticoid therapy after a glucocorticoid free interval of at least 4 months.

  • Ability to provide informed consent.

Exclusion Criteria:

  • Inability to provide informed consent.

  • Chronic glucocorticoid therapy for another condition.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Wilson Gonsalves, M.D.

Contact us for the latest status

Contact information:

Vanessa Fell

5072666068

fell.vanessa@mayo.edu

More information

Publications

Publications are currently not available